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year [1] . Despite its public health burden, nearly one third of the estimated cases are missed by national surveillance systems, suggesting that many cases fail to reach the health services. TB mortality is higher in patients with a late diagnosis, advanced disease stages and co-infection with HIV, and strategies which increase case detection and reach an early diagnosis are integral to the global strategy for the control of TB [2] .
One of the major problems for the management of TB is the inefficiency of the diagnostic cascade. Diagnostic investigations are usually triggered after a patient has had cough for two or more weeks and the tests used are unsuitable for rapid and large-scale screening.
The most frequently used tests, smear microscopy and Xpert MTB/RIF, are highly specific.
However, smear microscopy has low sensitivity and is technically unsuitable as a screening tool, and Xpert MTB/RIF and X-Rays require an infrastructure that is rarely available at peripheral diagnostic centres. It is recognised that diagnostic algorithms could be improved with the use of triage tests that select patients requiring further confirmatory tests and exclude patients unlikely to have TB [3] . The World Health Organization has included, among the high priority target product profiles (TPP) for TB diagnosis, a non-sputum-based triage test, which, under ideal conditions, would require sensitivity ≥95% and specificity >75% [4] . However, early promising prototypes for triage, such as a Beta Lactamase C assay [5] , failed to reach the production stages and the pipeline for these tests has very few candidates [6] .
Serum levels of acute phase proteins (APPs) and cytokines are increased in individuals with TB. Among these, C-reactive protein (C-RP) is often used in clinical practise as an adjuvant test for diagnosis (especially in children) [7] and interferon gamma-induced protein 10 (IP-M A N U S C R I P T A C C E P T E D ACCEPTED MANUSCRIPT 5 combination of sensitivity and specificity whereas triage tests require high sensitivity, to identify as many cases as possible, often at the expense of lower specificity.
There is renewed interest to explore whether APPs and cytokines could be used as triage tests for TB. As few studies have considered using APPs and IP-10 for screening purposes, we examined the data reported in studies for diagnostic purposes and discuss whether their intended use could be extended to triage, as rule in or rule out tests to select individuals who should undergo further confirmatory tests.
Methods

This study was conducted following the Cochrane Collaboration's Diagnosis Test Accuracy
Working Group protocol. Institutional review board approval and informed consent was not required for this systematic review and meta-analysis. A study protocol was designed a priori and was registered in the PROSPERO database (registration number CRD42018087015).
We reported our findings according to Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) guidelines.
Search strategy and selection criteria
We performed a systematic review using SCOPUS, PubMed and Web of Science databases to identify studies published without language restriction up to October 14, 2017. We used the search terms "acute phase proteins", "IP-10", "tuberculosis", "screening", "diagnosis" and related terms. The full search strategy is described in the Appendix. Two independent review authors (VSS and KK) screened the title and abstract for relevance and a third review author (LEC) was consulted to resolve disagreements. Articles considered to have original material were obtained and assessed in detail and the references cited in these publications were searched to identify further publications.
We included studies that met the following conditions: (1) The study used quantitative laboratory-based and/or point-of-care assays to measure levels of at least one of APP results, or these data were derivable from the published results. Articles were included regardless of age (adults or children) or if they had co-infections (e.g. HIV).
We excluded studies that only reported stimulated IP-10 values, but the authors of these studies were asked to provide the non-stimulated baseline results if available (e.g. the Nil values of the Quantiferon assay) to prepare additional Receiver Operating Curves (ROC) for meta-analysis. Studies that focused on latent Mycobacterial tuberculosis infections, those who tested patients after initiation of treatment and those that used samples other than blood (e.g. pulmonary biopsies or pleural exudates) and case-control studies were excluded.
Data extraction and bias assessment
We predefined tables for data extraction, which were piloted in 10 articles. The information extracted included author, country, study design, clinical setting (hospital or community) participant characteristics, case definition for TB diagnosis, markers included, method of detection and the threshold used for each marker. We extracted the absolute numbers of true-positive, false-positive, false-negative and true-negative test results from the paper or studies and the risk of bias were assessed by two independent reviewer authors using the QUADAS-2 guidelines as shown in the Material Supplementary. We used the RevMan software (version 5.3; Cochrane Collaboration) to generate the graphs on the risk of bias.
Statistical analysis
We used the sensitivity and specificity of the markers reported by the author or (re)calculated them from the data presented. For diagnostic performance of C-RP, we fitted the Hierarchical Summary Receiver Operating Characteristic (HSROC) model proposed by Rutter and Gatsonis [10] , which take into account correlation between sensitivity and specificity across studies while also allowing for variation in test performance between studies through the inclusion of random effects. We expected that the methods for measuring the markers and the cut-offs would vary across studies, and thus investigated potential methodological and assay differences to interpret variations in performance. An exploratory analysis to investigate potential factors of heterogeneity was performed by visual inspection of HSROC curves. Meta-regression was conducted by adding these factors as covariates to the hierarchical model [11] . The characteristics explored were the WHO TB burden classification of the country where the study took place (high-burden vs others), HIV status (positive vs negative), clinical settings (hospitalized vs community) and method for C-RP quantification. Publication bias was examined using the effective sample size funnel plot and associated regression test of asymmetry described by Deeks and colleagues [12] .
For IP-10, as few studies were available, the diagnostic performance was analysed by modelling the trade-off between sensitivity and specificity using the Moses SROC regression [13, 14] .
For all analyses Two-sided p < 0.05 values were considered statistically significant.
Statistical analyses were performed using the R statistical programming language (version 2.10.13; R Core Team, 2013) and STATA (version 14; Stata Corp LP).
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the article.
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Results
The search strategy identified 891 records. After screening titles and abstracts, 104 full-text articles were assessed for eligibility and 19 were included ( Figure 1 ). C-RP was reported in 14 studies [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] , IP-10 in four [29] [30] [31] [32] and alpha-1-acid glycoprotein [33] in one. Table 1 summarize the main characteristics of each study.
C-reactive protein
Six of the 14 studies reporting C-RP sensitivity and specificity included only HIV-infected individuals [16, 19, 24, [26] [27] [28] , four only HIV-uninfected [17, 21, 23, 25] , two both HIV-infected and HIV-uninfected patients [20, 22] and in two studies the HIV status was not described [15, 18] . Nine studies were conducted in high TB burden countries [15, 16, 20, 22, [24] [25] [26] [27] [28] . Nine studies enrolled patients in community settings [15, 17, 18, 22, [24] [25] [26] [27] [28] , five enrolled hospitalized patients [16, [19] [20] [21] 23] . All studies focused on adults. Most studies used a 10 mg/dl cut-off point ( Table 1 ).
The quality of the studies and the risk of bias are shown in appendix (see Supplementary eFigures 1 and 2). The QUADAS-2 tool showed that the studies that enrolled patients in the community had a lower risk of bias than studies enrolling hospitalized patients. Most studies enrolling community individuals were designed to evaluate the diagnostic accuracy of C-RP for TB and enrolled a representative spectrum of patients, whereas hospital studies did not provide sufficient information to determine the patient selection method and unclear blinding for the interpretation of results, which are potential sources of bias.
The overall (95%CI) pooled sensitivity of C-RP was 89% (80%-96%) with a pooled (95%CI) specificity of 57% (36%-65%) ( Table 2 ). The positive and negative likelihood ratio (95%CI) To investigate the potential sources for heterogeneity, we conducted a meta-regression analysis using the country TB burden, HIV status, clinical settings and C-RP assays. Of these, the most important source of heterogeneity was the clinical setting (Table 4 ). We also explored the performance for C-RP among HIV-infected patients from high TB burden countries. The pooled (95%CI) sensitivity for this group was 92% (89%-94%), with a pooled (95%CI) specificity of 66% (64%-68%).
No publication bias and high symmetry of the included studies were proved by Deeks' funnel plot asymmetry test (P = 0.73; Figure 3 ).
IP-10
Unstimulated IP-10 values were obtained from four studies [29] [30] [31] [32] (Table 1) . One studies included HIV-uninfected individuals [29] , two included both HIV-uninfected and HIV-infected patients [30, 32] and in one the HIV status was unknown [31] . Three studies [29] [30] [31] were conducted in adults and only one in children [32] . All studies used culture positive from sputum as the reference standard for the confirmation of cases. There was a wide variation in the kits and thresholds used, and many studies did not report the cut-offs selected, which precluded further analysis.
Most of the studies did not enrol a representative spectrum of patients or failed to provide satisfactory information to determine the patient selection methods. Furthermore, the unblinded interpretation of results, the lack of a pre-specified cut-off thresholds and the different assays used were common sources of potential bias (See Supplementary Figures 6   and 7 ).
As the studies included a wide range of populations (often without matched groups), it was not possible to estimate pooled sensitivity and specificity across the studies. The performance of unstimulated IP-10 test is thus presented for each group in Table 5 . The pooled (95%CI) sensitivity and specificity to diagnose TB was 85% (77%-92%) and 63% (54%-71%), respectively. Studies comparing patients with TB and HIV co-infection and patients with other lung diseases had an estimated sensitivity of 94% (80%-99%) and (95% 2.28 to 76.27); TB HIV+ vs Non-TB HIV+, 3.11 (95% 0.79 to 12.26).
Alpha-1-acid glycoprotein
Only one study [33] reported data for alpha-1-acid glycoprotein was included. This study enrolled 21 patients with TB and 27 patients with bacterial pneumonia. The sensitivity and specificity (95%CI) were 86% (64%-95%) and 93% (75%-98%), respectively.
There were no studies describing the combined use of C-RP with IP-10 or Alpha-1-acid glycoprotein to explore whether using two or more of these markers would result in a higher sensitivity.
Discussion
It is estimated that nearly 4.1 million TB cases are missed annually worldwide [1] and increasing the accessibility of diagnostic and treatment services is essential for its effective The screening of TB among HIV-infected individuals is also particularly challenging. A recent systematic review of C-RP for the screening of TB in patients with HIV however, reported unexpectedly good results in this high-risk group [34] .
Furthermore, although many studies have investigated IP-10 expression as a specific response to the in-vitro stimulation of white blood cells to specific TB antigens, few studies have reported its use in its steady -unstimulated -concentrations. Altered serum and/or tissue expression of IP-10 has been associated with inflammatory diseases, including organspecific or systemic autoimmune diseases [35] , neurological disorders [36] , vascular diseases [37, 38] , and viral and bacterial infections [39] . One previous meta-analysis [40] reported a pooled sensitivity and specificity of 73% and 82% for the diagnosis of TB.
However, this study included data of both stimulated and unstimulated IP-10, patients with pleural effusions and compared patients with TB and healthy controls, which limited its interpretation. In the current study, we focused on non-stimulated (in the absence of in vitro TB antigens) IP-10 in patients with pulmonary TB and requested datasets from investigators to conduct a reanalysis with a triage perspective. Although the number of studies is small, C-
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RP and IP-10 seem to have high sensitivity and moderate specificity as triage markers in patients with symptoms suggestive of active TB. Our data resulted in a C-RP pooled sensitivity and specificity of 89% and 57%, while the pooled sensitivity and specificity for IP-10 were 85% and 63%. Despite their low/moderate specificity, these performances would make them strong candidates for triage because, although they miss the TPP targets, their performance could potentially be improved by calculating optimal screening cut-offs in prospectively enrolled patients. Several semi-quantitative C-RP tests are also available in the market and their use as point of care devices for screening would increase the capacity of the health services to diagnose larger number of patients. IP-10 studies in turn, were judged to have a high risk of bias and high concern about applicability. Furthermore, the IP-10 studies included were considered to have a high risk of bias and thus the quality of evidence is very low at this stage.
Our findings therefore should be treated with caution as we faced important limitations. As expected, the performance of the markers varied with the burden of TB across settings, with a higher sensitivity and specificity in high burden countries. The higher sensitivity in these settings may reflect the late presentation of patients to health services and the higher frequency of co-morbidities, such as HIV, malaria and bacterial co-infections. The higher specificity may reflect the location used to enrol study participants, as most studies were based on TB diagnostic services, where the proportion of patients with TB would be higher than in general clinical services. Some studies also did not provide sufficient information to determine the patient selection method, with unclear blinding and some studies used inappropriate patient exclusions with potential to introduce bias. Furthermore, although there was no limitation in the search for children, most the articles limited their analyses to adults, which fixed the interpretations of our findings to this age group. As much as possible, data included comparisons between patients with and without a diagnosis of TB. Our findings therefore reflect the investigator-selected cut-offs, usually decided retrospectively by observing the data, which limited our ability to establish an appropriate threshold for screening across the studies. Other APPs, such as Alpha-1-acid glycoprotein should also be M A N U S C R I P T
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13 explored. Although this biomarker could have similar potential as C-RP for triage, we could only find one publication that met the inclusion criteria.
The results of these studies can be modelled in an scenario where C-RP assays were to be used in a high TB prevalence setting in a group of 1000 individuals with symptoms compatible with TB, where 200 (20%) are typically expected to have a positive TB culture (confirmed TB). In this scenario, the C-RP test would be followed by a confirmatory test (e.g.
Xpert MTB/RIF) with an estimated 75% sensitivity and 98% specificity. In this scenario, an 
